Wynn, Thomas A.
Pfizer Inc.,
United States
2025 Rank: 616
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Microbiology
Rank in SubField 1: 29 out of 166615 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 616 | 659 |
| Total Cites | 56223 | 59680 |
| H-index | 99 | 106 |
| Hm-index | 36 | 37 |
| Number of Single Authored Papers | 16 | 16 |
| Total Cites to Single Authored Papers | 8907 | 9019 |
| Number of Single+First Authored Papers | 42 | 42 |
| Total Cites to Single+First Authored Papers | 20909 | 21403 |
| Number of Single+First+Last Authored Papers | 121 | 121 |
| Total Cites to Single+First+Last Authored Papers | 42258 | 43990 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 42338 | 43652 |
| Ratio of Total Citations to Distinct Citing Papers | 1.33 | 1.37 |
| Self-Citation Percentage |
5.79%
|
|
Wynn, Thomas A.
Pfizer Inc.,
United States
2024 Rank: 611
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Microbiology
Rank in SubField 1: 31 out of 157372 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 611 | 666 |
| Total Cites | 51567 | 54907 |
| H-index | 98 | 105 |
| Hm-index | 35 | 36 |
| Number of Single Authored Papers | 15 | 15 |
| Total Cites to Single Authored Papers | 8292 | 8402 |
| Number of Single+First Authored Papers | 39 | 39 |
| Total Cites to Single+First Authored Papers | 18958 | 19435 |
| Number of Single+First+Last Authored Papers | 116 | 116 |
| Total Cites to Single+First+Last Authored Papers | 38280 | 39936 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 38682 | 39969 |
| Ratio of Total Citations to Distinct Citing Papers | 1.33 | 1.37 |
| Self-Citation Percentage |
6.08%
|
|
Wynn, Thomas A.
Pfizer Inc.,
United States
2023 Rank: 633
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Microbiology
Rank in SubField 1: 30 out of 147556 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 633 | 683 |
| Total Cites | 46904 | 50175 |
| H-index | 97 | 104 |
| Hm-index | 35 | 36 |
| Number of Single Authored Papers | 15 | 15 |
| Total Cites to Single Authored Papers | 7615 | 7725 |
| Number of Single+First Authored Papers | 39 | 39 |
| Total Cites to Single+First Authored Papers | 17023 | 17497 |
| Number of Single+First+Last Authored Papers | 116 | 116 |
| Total Cites to Single+First+Last Authored Papers | 34398 | 36030 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 35012 | 36261 |
| Ratio of Total Citations to Distinct Citing Papers | 1.34 | 1.38 |
| Self-Citation Percentage |
6.52%
|
|
Wynn, Thomas A.
National Institute of Allergy and Infectious Diseases (NIAID),
United States
2022 Rank: 662
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Microbiology
Rank in SubField 1: 31 out of 138599 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 662 | 701 |
| Total Cites | 41824 | 44980 |
| H-index | 93 | 101 |
| Hm-index | 35 | 36 |
| Number of Single Authored Papers | 15 | 15 |
| Total Cites to Single Authored Papers | 6940 | 7048 |
| Number of Single+First Authored Papers | 39 | 39 |
| Total Cites to Single+First Authored Papers | 15031 | 15501 |
| Number of Single+First+Last Authored Papers | 116 | 116 |
| Total Cites to Single+First+Last Authored Papers | 30354 | 31948 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 31040 | 32219 |
| Ratio of Total Citations to Distinct Citing Papers | 1.35 | 1.40 |
| Self-Citation Percentage |
7.02%
|
|
Wynn, Thomas A.
Pfizer Inc.,
United States
2021 Rank: 665
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Microbiology
Rank in SubField 1: 32 out of 127911 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 665 | 723 |
| Total Cites | 39519 | 42599 |
| H-index | 91 | 98 |
| Hm-index | 34 | 36 |
| Number of Single Authored Papers | 15 | 15 |
| Total Cites to Single Authored Papers | 6610 | 6718 |
| Number of Single+First Authored Papers | 39 | 39 |
| Total Cites to Single+First Authored Papers | 14121 | 14585 |
| Number of Single+First+Last Authored Papers | 116 | 116 |
| Total Cites to Single+First+Last Authored Papers | 28530 | 30092 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 29270 | 30421 |
| Ratio of Total Citations to Distinct Citing Papers | 1.35 | 1.40 |
| Self-Citation Percentage |
7.23%
|
|
Wynn, Thomas A.
National Institute of Allergy and Infectious Diseases,
United States
2020 Rank: 770
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Microbiology
Rank in SubField 1: 38 out of 108509 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 770 | 801 |
| Total Cites | 33989 | 36962 |
| H-index | 86 | 95 |
| Hm-index | 33 | 34 |
| Number of Single Authored Papers | 14 | 14 |
| Total Cites to Single Authored Papers | 5812 | 5920 |
| Number of Single+First Authored Papers | 38 | 38 |
| Total Cites to Single+First Authored Papers | 11794 | 12255 |
| Number of Single+First+Last Authored Papers | 113 | 113 |
| Total Cites to Single+First+Last Authored Papers | 24061 | 25593 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 25009 | 26096 |
| Ratio of Total Citations to Distinct Citing Papers | 1.36 | 1.42 |
| Self-Citation Percentage |
8.04%
|
|
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.